title: The Effect of Intradialytic Intralipid Therapy in Pediatric Hemodialysis Patients.
abstract: Growth of children on maintenance hemodialysis is poor. Oral nutritional supplements are the preferred way to augment nutrition; however, many children have difficulties adhering to prescribed oral supplements. In our unit, we have been utilizing intralipid (IL) therapy as nutritional supplement during hemodialysis sessions. The aim of this study was to assess the safety, efficacy, and benefits of intradialytic IL therapy.
  
  
  
  A retrospective chart review.
  
  
  
  Fifteen pediatric hemodialysis patients receiving intradialytic IL therapy for at least 3 months from July 2011 through July 2014.
  
  
  
  For each patient, anthropometric measurements and laboratory nutritional parameters were compared prior to and at the end of IL therapy. Anthropometric measurements evaluated were dry weight, height, body mass index (BMI), and BMI corrected for height age. Laboratory nutritional parameters evaluated were albumin, normalized protein catabolic rate, predialysis blood urea nitrogen, transferrin, cholesterol, and triglyceride levels. Adverse events during therapy were also noted.
  
  
  
  Significant improvement was noted in albumin levels, predialysis blood urea nitrogen, and normalized protein catabolic rate during therapy (P = .02; P = .03; P = .03, respectively). Six patients (37.5%) improved their weight standard deviation score, and eight patients (50%) improved their BMI standard deviation score though not statistically significant (P = .59; P = .9, respectively). No significant side effects were noted.
  
  
  
  Administration of IL alone during hemodialysis is well tolerated with beneficial effects on nutritional parameters. The provision of IL alone is relatively cheap and does not require additional resources. In conjunction with other measures of nutritional support, it can help improve nutritional status of pediatric hemodialysis patients.
authors.affiliation: Pediatric Nephrology Department, Schneider's Children Medical Center of Israel, Petah-Tikva, Israel. Electronic address: orly.haskin@gmail.com.
authors.forename: Orly
authors.initials: O
authors.lastname: Haskin
authors.affiliation: Pediatric Nephrology Department, Stanford University School of Medicine, Stanford, California.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Sutherland
authors.affiliation: Pediatric Nephrology Department, Stanford University School of Medicine, Stanford, California.
authors.forename: Cynthia J
authors.initials: CJ
authors.lastname: Wong
mesh_terms: D000293:Adolescent; D000328:Adult; D001806:Blood Urea Nitrogen; D015992:Body Mass Index; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D004032:Diet; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004655:Emulsions / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D009752:Nutritional Status; D010743:Phospholipids / Q000008:administration & dosage*; D006435:Renal Dialysis; D012189:Retrospective Studies; D000075462:Serum Albumin, Human / Q000032:analysis; D013024:Soybean Oil / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D004655:Emulsions; D010743:Phospholipids; C545823:soybean oil, phospholipid emulsion; D013024:Soybean Oil; D000075462:Serum Albumin, Human